By Adriano Marchese


Lantheus Holdings is being sued by Swiss multinational pharmaceutical Novartis for patent infringement on a generic drug to treat specific types of neuroendocrine tumors.

According to recent filings to the Securities and Exchange Commission, the diagnostic medical imaging agents and products company and its subsidiary, Lantheus Medical Imaging, are being sued by two Novartis entities, Advanced Accelerator Applications USA and Advanced Accelerator Applications.

The company is being taken to court for patent infringement in response to its filing of the abbreviated new drug application for Lutetium, a generic version of Lutathera, indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.


Write to Adriano Marchese at adriano.marchese@wsj.com


(END) Dow Jones Newswires

01-26-24 0840ET